The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition
Open accessAbstract
Accumulation and deposition of amyloid-β (Aβ) in the brain represent an early and perhaps necessary step in the pathogenesis of Alzheimer's disease (AD). Aβ accumulation leads to the formation of Aβ aggregates, which may directly and indirectly lead to eventual neurodegeneration. While Aβ production is accelerated in many familial forms of early-onset AD, increasing evidence indicates that impaired clearance of Aβ is more evident in late-onset AD. To uncover the mechanisms underlying impaired Aβ clearance in AD, we examined the role of low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. Although LRP1 has been shown to play critical roles in brain Aβ metabolism in neurons and vascular mural cells, its role in astrocytes, the most abundant cell type in the brain responsible for maintaining neuronal homeostasis, remains unclear. Here, we show that astrocytic LRP1 plays a critical role in brain Aβ clearance. LRP1 knockdown in primary astrocytes resulted in decreased cellular Aβ uptake and degradation. In addition, silencing of LRP1 in astrocytes led to downregulation of several major Aβ-degrading enzymes, including matrix metalloproteases MMP2, MMP9, and insulin-degrading enzyme. More important, conditional knock-out of the Lrp1 gene in astrocytes in the background of APP/PS1 mice impaired brain Aβ clearance, exacerbated Aβ accumulation, and accelerated amyloid plaque deposition without affecting its production. Together, our results demonstrate that astrocytic LRP1 plays an important role in Aβ metabolism and that restoring LRP1 expression and function in the brain could be an effective strategy to facilitate Aβ clearance and counter amyloid pathology in AD. SIGNIFICANCE STATEMENT Astrocytes represent a major cell type regulating brain homeostasis; however, their roles in brain clearance of amyloid-β (Aβ) and underlying mechanism are not clear. In this study, we used both cellular models and conditional knock-out mouse models to address the role of a critical Aβ receptor, the low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. We found that LRP1 in astrocytes plays a critical role in brain Aβ clearance by modulating several Aβ-degrading enzymes and cellular degradation pathways. Our results establish a critical role of astrocytic LRP1 in brain Aβ clearance and shed light on specific Aβ clearance pathways that may help to establish new targets for AD prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This family of receptors have essential roles in lipid and cholesterol transport, with LRP1 also implicated in the astrocytic uptake and degradation of amyloid-β [106-108].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [107]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which has been implicated in the uptake and degradation of amyloid-β and tau [107, 147].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [107]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clearance of Aβ through direct association with ApoE or through binding to ApoE receptors decreases amyloid pathology in mouse models.”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR, LRP1 and ApoER2 receptors are also present in astrocytes [15,24,63] and have been also shown to be involved in the Aβ clearance mediated by astrocytes [50,64].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, receptors that bind to apoE have been shown to influence amyloid pathology. 21 , 41”
From Deletion of miR-33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice (2024) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“has also been implicated in AD pathology. 21 , 32 , 33”
The cited source says what the claim attributes to it.
In the citing paper
“LRP1 is a widely expressed receptor that was previously shown to enhance Aβ uptake, clearance, and degradation. 21”
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, knockout of LRP1 in astrocytes decreases Aβ clearance and increases Aβ pathology [85, 87].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“astrocytic LDLR and LRP1 have been shown to be involved in Aβ uptake and clearance, as confirmed by the significant change in Aβ accumulation observed in experimental models characterized by the knockdown or the overexpression of one of these two receptors [50,64,76]”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Cellular receptors such as low-density lipoprotein receptor-related protein 1 (LRP1) [47–50], LRP8 [51], LDLR [52] or RAGE [53] may also affect APP metabolism by either modulating the activities of β- and γ-secretase and/or directly Aβ levels through endocytosis.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Interestingly, Apoe-deficient astrocytes upregulate genes associated with inhibition of Aβ fibrillization (Ptgds and Cst3) and regulation of protein degradation (Ubb, Ubc and Ctsl) (Apelt et al, 2003; Davis et al, 2021; Liu et al, 2017a; Wegiel et al, 2000).”
From APOE from astrocytes restores Alzheimer’s Aβ-pathology and DAM-like responses in APOE deficient microglia (2024) · cites this paper as Liu et al, 2017a
Experimental — accuracy not yet measuredIn the citing paper
“AD is accompanied by activation of microglia and astrocytes1,2 that affects the clearance and production of Aβ42,3,4 development and propagation of tau pathology,5 exacerbates neurodegeneration, and influences disease progression and severity.6,7”
From CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease (2018) · cites this paper as [4]
In the citing paper
“the low‐density lipoprotein receptor‐related protein 1 (LRP1) plays an important role in Aβ degradation and transport across the blood–brain barrier (Kanekiyo et al., 2011, 2013; Liu et al., 2017; Ma et al., 2018; Shibata et al., 2000; Storck et al., 2016)”
From Alzheimer's amyloid‐β and tau protein accumulation is associated with decreased expression of the LDL receptor‐associated protein in human brain tissue (2020) · cites this paper as Liu et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Self-citationBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,684
Lentivirus-delivered stable gene silencing by RNAi in primary cells.
Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D., Sabatini, D., Chen, I. S. Y., Hahn, W., Sharp, P., et al. (2003) · RNA: A publication of the RNA Society · doi:10.1261/rna.2192803 · Cited by 1,619
Cited by
Sorted by citations
Items 101–200 of 270
Stanca, S., Rossetti, M., & Bongioanni, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813880 · Cited by 35
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 37
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
Role of astrocytes in sleep deprivation: accomplices, resisters, or bystanders?
Que, M., Li, Y., Wang, X., Zhan, G., Luo, X., & Zhou, Z. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1188306 · Cited by 35
The Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 31
García-Fernández, P., Üçeyler, N., & Sommer, C. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000898 · Cited by 32
Fujita, Y., Kano, K., Kishino, S., Nagao, T., Shen, X., Sato, C., Hatakeyama, H., Ota, Y., Niibori, S., Nomura, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88870-9 · Cited by 31
Auderset, L., Pitman, K. A., Cullen, C. L., Pepper, R. E., Taylor, B. V., Foa, L., & Young, K. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564351 · Cited by 30
Gulej, R., Patai, R., Ungvari, A., Kállai, A., Tarantini, S., Yabluchanskiy, A., Huffman, D. M., Conboy, M. J., Conboy, I. M., Mika Kivimaki, B., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01657-y · Cited by 29
Yue, X., Zhou, Y., Qiao, M., Zhao, X., Huang, X. H., Zhao, T., Cheng, X., Fan, M., Zhao, Y., Chen, R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00935-z · Cited by 30
Fu, Y., Zhang, J., Qin, R., Ren, Y., Zhou, T., Han, B., & Liu, B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100053 · Cited by 29
Astrocyte adaptation in Alzheimer’s disease: a focus on astrocytic P2X7R
Beltran-Lobo, P., Reid, M. J., Jiménez-Sánchez, M., Verkhratsky, A., Perez‐Nievas, B. G., & Noble, W. J. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220079 · Cited by 30
Pilat, D., Paumier, J.-M., García-González, L., Louis, L., Stephan, D., Manrique, C., Khrestchatisky, M., Di Pasquale, E., Baranger, K., & Rivera, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02407-z · Cited by 28
Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology
Gouilly, D., Rafiq, M., Nogueira, L., Salabert, A., Payoux, P., Péran, P., & Pariente, J. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.006 · Cited by 31
Guha, S., Paidi, R. K., Goswami, S., Saha, P., & Biswas, S. C. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.11.021 · Cited by 26
de Oliveira, J., Moreira, E. L. G., & Bem, A. F. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102149 · Cited by 26
Li, W., Chen, C., Xu, B., Chen, J., Yang, M., Gao, L., & Zhou, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116643 · Cited by 27
Chen, K., Morizawa, Y. M., Nuriel, T., Al‐Dalahmah, O., Xie, Z., & Yang, G. (2025) · Neuron · doi:10.1016/j.neuron.2025.04.027 · Cited by 27
Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses
Kadamangudi, S., Marcatti, M., Zhang, W.-R., Fracassi, A., Kayed, R., Limon, A., & Taglialatela, G. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02839-2 · Cited by 25
Pan, X., Zz, L., Gg, J., Lp, W., Cm, B., Yl, W., Chen, M. F., & Li, W. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105417 · Cited by 26
Jin, H. M., Peng, X., He, Y., Ruganzu, J. B., & Yang, W. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.08.019 · Cited by 26
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
Tian, M., Kawaguchi, R., Shen, Y., Machnicki, M., Villegas, N. G., Cooper, D. R., Montgomery, N., Cai, Y., Haring, J., Lan, R., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.002 · Cited by 24
Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy
Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 28
Self-citationApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes
Eisenbaum, M., Pearson, A., Ortiz, C., Mullan, M., Crawford, F., Ojo, J., & Bachmeier, C. (2024) · Glia · doi:10.1002/glia.24469 · Cited by 25
Staurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease
Tsoy, A., Umbayev, B. A., Kassenova, A., Kaupbayeva, B., & Askarova, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010964 · Cited by 24
Macyczko, J. R., Wang, N., Zhao, J., Ren, Y., Lü, W., Ikezu, T. C., Zhao, N., Liu, C., Bu, G., & Li, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03065-1 · Cited by 25
Self-citationGe, J., Koutarapu, S., Jha, D., Dulewicz, M., Zetterberg, H., Blennow, K., & Hanrieder, J. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05302 · Cited by 24
APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease
Ayyubova, G. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230303114425 · Cited by 23
Chlamydia pneumoniae in Alzheimer's disease pathology
Subedi, L., Gaire, B. P., Koronyo, Y., Koronyo‐Hamaoui, M., & Crother, T. R. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1393293 · Cited by 24
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 24
Herrero-Labrador, R., Trueba-Sáiz, Á., Martinez‐Rachadell, L., de Sevilla, M. E. F., Zegarra-Valdivia, J. A., Pignatelli, J., Díaz-Pacheco, S., Fernandez, A. M., & Torres‐Alemán, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249675 · Cited by 22
Romeo, R., Mourabit, D. B.-E., Scheller, A., Mark, M. D., & Faissner, A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.642521 · Cited by 21
Pan, T.-T., Sun, Y., Shi, Y.-F., Zhao, M., Khan, N. U., Chen, H., Ji, W., Li, J., Han, L., & Ma, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01840-5 · Cited by 19
Shruthi, N. R., Behera, M. M., Naik, S. K., Das, S. K., Gopan, S., Ghosh, A. K., Sahu, R. N., Patra, S., & Purkait, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1003730 · Cited by 20
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Wu, B., Liu, Y., Li, H., Zhu, L., Zeng, L., Zhang, Z., & Peng, W. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391305 · Cited by 22
Proust, A. M., Barat, C., Lebœuf, M., Drouin, J., Gagnon, M., Vanasse, F., & Tremblay, M. J. (2020) · Glia · doi:10.1002/glia.23833 · Cited by 19
Lv, C., Niu, S., Yan, S., Bai, C., Yu, X., Hou, J., Gao, W., Zhang, J., Zhao, Z., Yang, C., et al. (2019) · Poultry Science · doi:10.3382/ps/pez168 · Cited by 19
Sleep Disturbance and Alzheimer’s Disease: The Glial Connection
Sunkaria, A., & Bhardwaj, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03578-0 · Cited by 19
Yadav, V., Mythri, C., & Kumarasamy, M. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100048 · Cited by 22
Peripheral HMGB1 is linked to O3 pathology of disease‐associated astrocytes and amyloid
Ahmed, C., Greve, H. J., Garza-Lombó, C., Malley, J. A., Johnson, J., Oblak, A. L., & Block, M. L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13825 · Cited by 18
Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease
Kim, D., & Priefer, R. (2020) · Brain Sciences · doi:10.3390/brainsci10020093 · Cited by 18
Clark, A. T., Abrahamson, E. E., Harper, M. M., & Ikonomović, M. D. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00301-z · Cited by 18
Experimental approaches for altering the expression of Abeta‐degrading enzymes
Loeffler, D. A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15762 · Cited by 18
Niazi, N. U. K., Huang, C.-Y., Yang, Z., Zhang, Y., & Song, C. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115067 · Cited by 17
Engulfment of Toxic Amyloid β-protein in Neurons and Astrocytes Mediated by MEGF10
Fujita, Y., Maeda, T., Sato, C., Sato, M., Hatakeyama, H., Ota, Y., Iwabuchi, N., Tatesawa, K., Nomura, A., Zou, K., et al. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.07.016 · Cited by 17
Romeo, R., Glotzbach, K., Scheller, A., & Faissner, A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.567253 · Cited by 17
Tate, M., Wijeratne, H. R. S., Kim, B., Philtjens, S., You, Y., Lee, D., Gutierrez, D. A., Sharify, D., Wells, M., Perez‐Cardelo, M., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14243 · Cited by 21
“21,41 Because the deletion of mir-33 regulates apoElipidation,weaimedtodeterminewhethertheexpressionofapoE receptors was affected.”
Faissner, A. (2023) · Frontiers in Network Physiology · doi:10.3389/fnetp.2023.1190240 · Cited by 17
Bone Marrow‐Derived GCA+ Immune Cells Drive Alzheimer's Disease Progression
Zhou, R., Wang, L., Chen, L., Xu, F., Zhou, R., Peng, X. F., Wen, J., Huang, Y., & Zhou, H. (2023) · Advanced Science · doi:10.1002/advs.202303402 · Cited by 16
Refining the interactions between microglia and astrocytes in Alzheimer’s disease pathology
Chen, J., Xu, S., Wang, L., Liu, X., Liu, G., Tan, Q., Li, W., Zhang, S., & Du, Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.033 · Cited by 17
Cai, H., Cai, T., Zheng, H., Liu, L., Zhou, L., Xile, P., Zhan, Q., Wang, Y., Yang, C., Guo, Z., et al. (2020) · Rejuvenation Research · doi:10.1089/rej.2019.2182 · Cited by 16
Key brain cell interactions and contributions to the pathogenesis of Alzheimer’s disease
Saavedra, J., Nascimento, M., Liz, M. A., & Cardoso, I. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1036123 · Cited by 16
Durand, D., Turati, J., Rudi, M. J., Ramírez, D., Saba, J., Caruso, C. M., Carniglia, L., Rommy von Bernhardi, M., & Lasaga, M. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104547 · Cited by 17
Inflammatory Cytokine IL-1β Downregulates Endothelial LRP1 via MicroRNA-mediated Gene Silencing
Hsu, H.-W., Rodríguez‐Ortiz, C. J., Zumkehr, J., & Kitazawa, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.021 · Cited by 16
Beta-Secretase 1 Underlies Reactive Astrocytes and Endothelial Disruption in Neurodegeneration
Chacón-Quintero, M. V., Pineda-López, L. G., Villegas‐Lanau, C. A., Posada‐Duque, R., & Cardona‐Gómez, G. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.656832 · Cited by 15
New Insights into lncRNAs in Aβ Cascade Hypothesis of Alzheimer’s Disease
Hao, Y., Xie, B., Fu, X., Xu, R., & Yang, Y. F. (2022) · Biomolecules · doi:10.3390/biom12121802 · Cited by 16
Zheng, M., Yang, Z., Cai, S.-L., Zheng, L., Xue, Y., Chen, L., & Lin, J. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107957 · Cited by 15
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 16
Hanas, J. S., Hocker, J. R. S., Lerner, M. R., & Couch, J. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215762 · Cited by 14
Wendt, S., Lin, A. J., Ebert, S. N., Brennan, D. J., Cai, W., Bai, Y., Kong, D. Y., Sorrentino, S., Groten, C. J., Lee, C., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03433-3 · Cited by 13
Wiersema, A. F., Rennenberg, A., Smith, G., Varderidou‐Minasian, S., & Pasterkamp, R. J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05522-7 · Cited by 13
Exosomes and non-coding RNAs: bridging the gap in Alzheimer’s pathogenesis and therapeutics
Chunhui, G., You, Y., Chen, J., Luo, N., & Li, F. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01520-7 · Cited by 13
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 13
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases
Choi, Y., & Chung, W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00870-9 · Cited by 14
Stevenson, T. K., Moore, S. J., Murphy, G. G., & Lawrence, D. A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1740265 · Cited by 12
Research progress of PPARγ regulation of cholesterol and inflammation in Alzheimer's disease
Gu, L., Ju, Y., Hu, M. S., Miao, Z., Li, Q., & Zhang, X. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-022-01139-6 · Cited by 12
Soler, Y., Rodriguez, M., Austin, D., Gineste, C., Gelber, C., & El‐Hage, N. (2023) · Cells · doi:10.3390/cells12040632 · Cited by 12
Cerebral biomimetic nano-drug delivery systems: A frontier strategy for immunotherapy
Tian, H., Yao, J., Ba, Q., Meng, Y., Cui, Y., Quan, L., Gong, W., Wang, Y., Yang, Y., Yang, M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.058 · Cited by 12
Regulation of Alzheimer's disease-associated proteins during epileptogenesis
von Rüden, E., Zellinger, C., Gedon, J., Walker, A., Bierling, V., Deeg, C. A., Hauck, S. M., & Potschka, H. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.08.037 · Cited by 11
Shepherd, C. E., Affleck, A. J., Bahar, A. Y., Carew‐Jones, F., Gregory, G., Small, D. H., & Halliday, G. M. (2020) · Brain and Behavior · doi:10.1002/brb3.1672 · Cited by 11
Apolipoprotein E isoform does not influence trans-synaptic spread of tau pathology in a mouse model
Davies, C., Tulloch, J., Yip, E., Currie, L., Colom‐Cadena, M., Wegmann, S., Hyman, B. T., Wilkins, L., Hooley, M., Tzioras, M., et al. (2023) · Brain and Neuroscience Advances · doi:10.1177/23982128231191046 · Cited by 11
Arispe, N. J., & Maio, A. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180161 · Cited by 11
Chaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.009 · Cited by 10
Takano-Kawabe, K., Matoba, K., Nakamura, Y., & Moriyama, M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04022-7 · Cited by 10
Optogenetics in Alzheimer’s Disease: Focus on Astrocytes
Mitroshina, Е. V., Kalinina, E. P., & Vedunova, M. V. (2023) · Antioxidants · doi:10.3390/antiox12101856 · Cited by 11
Hu, W., Liu, J., Hu, Y., Xu, Q., Deng, T., Wei, M., Lu, L., Mi, J., Bergquist, J., Xu, F., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1044022 · Cited by 9
GULP1/CED-6 ameliorates amyloid-β toxicity in a Drosophila model of Alzheimer’s disease
Chiu, W. Y. V., Koon, A. C., Ngo, J. C. K., Chan, H. Y. E., & Lau, K. (2017) · Oncotarget · doi:10.18632/oncotarget.20062 · Cited by 10
Neuropathological links between T2DM and LOAD: systematic review and meta-analysis
Lemche, E., Hortobágyi, T., Kiecker, C. M., & Turkheimer, F. (2025) · Physiological Reviews · doi:10.1152/physrev.00040.2024 · Cited by 9
Ghanbarian, E., Khorsand, B., Petersen, K. K., Nallapu, B. T., Sajjadi, S. A., Lipton, R. B., Ezzati, A., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251335915 · Cited by 8
DKK3-LRP1 complex and a chemical inhibitor regulate Aβ clearance in models of Alzheimer’s disease
Yang, R., Wang, L., Li, Y., Zhu, J., Wang, J., Schlessinger, D., & Sima, J. (2025) · Science Advances · doi:10.1126/sciadv.adz2099 · Cited by 8
Self-citationHovde, M. J., Maaser‐Hecker, A., Bae, J., & Tanzi, R. E. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70879 · Cited by 8
Guo, X., Bao, X., Wang, X., Liu, D., Liu, P., Chi, T., Ji, X., Zheng, Z., Chen, G., & Zou, L. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00209 · Cited by 8
Crosstalk between peripheral immunity and central nervous system in Alzheimer’s disease
Yang, H.-C., Qin, Q., Wang, M., Yin, Y., Li, R., & Tang, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104743 · Cited by 9
Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine
Maisam, M., Khan, M. T., Lodhi, M. S., Mou, K., Liu, Z., & Wei, D. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810258 · Cited by 7
Davis, G. H., Zaya, A., & Pearce, M. M. P. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1256-23.2024 · Cited by 7
Astrocyte–Neuron Interactions in Alzheimer’s Disease
Muñoz‐Castro, C., & Serrano‐Pozo, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-64839-7_14 · Cited by 7
Aquaporin-4 Mediated Aggregation of Alzheimer’s Amyloid β-Peptide
Maroli, N. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00233 · Cited by 7
Tran, V. T. A., Etemadi, N., Tran, M., Lee, J., Ko, H. S., Jo, D., Lee, L. P., & Cho, H. (2025) · BioChip Journal · doi:10.1007/s13206-025-00203-4 · Cited by 6
Ramachandran, A. K., Das, S., Shenoy, G. G., Mudgal, J., & Joseph, A. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666221226145141 · Cited by 7
Liu, R., Deng, Q., Gong, L., & Yang, L. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01598-2 · Cited by 5
Huang, N., Hong, R., Cui, X., Cao, L., Shi, L., Chen, B., Su, Y., Xu, X., Hua, C., & Ying, T. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04297-2 · Cited by 5
The identification of a Distinct Astrocyte Subtype that Diminishes in Alzheimer’s Disease
Wei, H., Withrow, J. S., Rakshit, J., Amin, F. U., Nahm, J., Mowry, F. E., Mao, Z., Bhattacharjee, M. B., Zhu, J., Yang, Y., et al. (2024) · Aging and Disease · doi:10.14336/ad.2024.0205-1 · Cited by 7
Astrocytes phenomics as new druggable targets in healthy aging and Alzheimer’s disease progression
Lana, D., Ugolini, F., Iovino, L., Attorre, S., & Giovannini, M. G. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1512985 · Cited by 6
SPROUT: spectral sparsification helps restore the spatial structure at single-cell resolution
Wang, J., Li, S., Chen, L., & Li, S. C. (2022) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqac069 · Cited by 6
Self-citationAmyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
Schreiner, T. G., & Popescu, B. O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245986 · Cited by 5
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Metadata
- Authors
- Liu, C.-C., Hu, J., Zhao, N., Wang, J., Wang, N., Cirrito, J. R., Kanekiyo, T., Holtzman, D. M., & Bu, G.
- Affiliations
- Mayo Clinic (US)
- Washington University in St. Louis (US)
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-03-08
- Volume
- 37
- Issue
- 15
- Pages
- 4023-4031
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC5391682
- OpenAlex
- W2593036876
- Cited by
- 267
- References
- 75
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 27 · 2023: 32 · 2022: 29 · 2021: 32 · 2020: 36 · 2019: 26 · 2018: 13 · 2017: 10
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- American Heart Association (15SDG22460003)
- National Institutes of Health
- National Institute on Aging (RF1AG051504, R01AG027924, RF1AG046205, R01AG046205, R01AG035355, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- LRP1, astrocytes, amyloid-beta clearance, Alzheimer's disease, amyloid deposition, amyloid plaques, matrix metalloproteinases, insulin-degrading enzyme, APP/PS1 mice, conditional knockout
- MeSH terms
- Animals, Astrocytes, Brain, Cells, Cultured, Female, Humans, Male, Peptide Fragments, Receptors, LDL, Amyloid beta-Peptides, Mice, Knockout, Tumor Suppressor Proteins, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
